{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:57:25Z","timestamp":1793228245414,"version":"4.5.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82430057, 82030092"],"award-info":[{"award-number":["82430057, 82030092"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473338"],"award-info":[{"award-number":["82473338"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Tianjin Key Medical Discipline(Specialty)Construction Projec(TJYXZDXK-009A)."},{"DOI":"10.13039\/501100006606","name":"Natural Science Foundation of Tianjin City","doi-asserted-by":"publisher","award":["24JCYBJC00580"],"award-info":[{"award-number":["24JCYBJC00580"]}],"id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02641-4","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:03:14Z","timestamp":1777334594000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeting GPR34 in damage-associated macrophages enhances anti-tumor immunity and the efficacy of Surufatinib in pancreatic cancer"],"prefix":"10.1038","volume":"11","author":[{"given":"Xiaofan","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianchen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopeng","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuning","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peijun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjie","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zekun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyang","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiansuo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3205-8544","authenticated-orcid":false,"given":"Xiuchao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuntao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1967-3593","authenticated-orcid":false,"given":"Xuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3435-6550","authenticated-orcid":false,"given":"Jun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihui","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"2641_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H. & Jemal, A. Cancer statistics, 2025. CA-Cancer J. Clin. 75, 10\u201345 (2025).","journal-title":"CA-Cancer J. Clin."},{"key":"2641_CR2","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/s41568-024-00706-6","volume":"24","author":"R Polak","year":"2024","unstructured":"Polak, R., Zhang, E. T. & Kuo, C. J. Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment. Nat. Rev. Cancer 24, 523\u2013539 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"2641_CR3","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.trecan.2024.03.008","volume":"10","author":"T Yasuda","year":"2024","unstructured":"Yasuda, T. & Wang, Y. A. Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development. Trends Cancer 10, 627\u2013642 (2024).","journal-title":"Trends Cancer"},{"key":"2641_CR4","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1158\/2159-8290.CD-22-0876","volume":"13","author":"C Falcomat\u00e0","year":"2023","unstructured":"Falcomat\u00e0, C. et al. Context-Specific Determinants of the Immunosuppressive Tumor Microenvironment in Pancreatic Cancer. Cancer Discov. 13, 278\u2013297 (2023).","journal-title":"Cancer Discov."},{"key":"2641_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01428-1","volume":"20","author":"X Mao","year":"2021","unstructured":"Mao, X. et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol. Cancer 20, 131 (2021).","journal-title":"Mol. Cancer"},{"key":"2641_CR6","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.molmed.2023.03.002","volume":"29","author":"R Rebelo","year":"2023","unstructured":"Rebelo, R., Xavier, C. P. R., Giovannetti, E. & Vasconcelos, M. H. Fibroblasts in pancreatic cancer: molecular and clinical perspectives. Trends Mol. Med 29, 439\u2013453 (2023).","journal-title":"Trends Mol. Med"},{"key":"2641_CR7","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1038\/s41423-024-01216-z","volume":"21","author":"A Mantovani","year":"2024","unstructured":"Mantovani, A. et al. Macrophage diversity in cancer dissemination and metastasis. Cell. Mol. Immunol. 21, 1201\u20131214 (2024).","journal-title":"Cell. Mol. Immunol."},{"key":"2641_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105278","volume":"107","author":"N V\u00e1zquez-Bell\u00f3n","year":"2024","unstructured":"V\u00e1zquez-Bell\u00f3n, N., Mart\u00ednez-Bosch, N., Garc\u00eda de Frutos, P. & Navarro, P. Hallmarks of pancreatic cancer: spotlight on TAM receptors. EBioMedicine 107, 105278 (2024).","journal-title":"EBioMedicine"},{"key":"2641_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1481247","volume":"15","author":"Q Wang","year":"2024","unstructured":"Wang, Q., Wang, J., Xu, K. & Luo, Z. Targeting the CSF1\/CSF1R signaling pathway: an innovative strategy for ultrasound combined with macrophage exhaustion in pancreatic cancer therapy. Front. Immunol. 15, 1481247 (2024).","journal-title":"Front. Immunol."},{"key":"2641_CR10","doi-asserted-by":"publisher","first-page":"6071","DOI":"10.1158\/0008-5472.CAN-21-3603","volume":"81","author":"WJ Ho","year":"2021","unstructured":"Ho, W. J. et al. Macrophage-Targeting by CSF1\/1R Blockade in Pancreatic Cancers. Cancer Res 81, 6071\u20136073 (2021).","journal-title":"Cancer Res"},{"key":"2641_CR11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40425-017-0257-y","volume":"5","author":"MA Cannarile","year":"2017","unstructured":"Cannarile, M. A. et al. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J. Immunother. Cancer 5, 53 (2017).","journal-title":"J. Immunother. Cancer"},{"key":"2641_CR12","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s40265-021-01489-y","volume":"81","author":"YY Syed","year":"2021","unstructured":"Syed, Y. Y. Surufatinib: First Approval. Drugs 81, 727\u2013732 (2021).","journal-title":"Drugs"},{"key":"2641_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13149","volume":"34","author":"MA Ali","year":"2022","unstructured":"Ali, M. A. et al. Efficacy and toxicity of surufatinib in neuroendocrine tumors: A systematic review and meta-analysis. J. Neuroendocrinol. 34, e13149 (2022).","journal-title":"J. Neuroendocrinol."},{"key":"2641_CR14","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211042689","volume":"13","author":"J Xu","year":"2021","unstructured":"Xu, J. et al. Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs). Ther. Adv. Med. Oncol. 13, 17588359211042689 (2021).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"2641_CR15","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/S1470-2045(20)30496-4","volume":"21","author":"J Xu","year":"2020","unstructured":"Xu, J. et al. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 21, 1500\u20131512 (2020).","journal-title":"Lancet Oncol."},{"key":"2641_CR16","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/s41568-024-00714-6","volume":"24","author":"MA Harris","year":"2024","unstructured":"Harris, M. A. et al. Towards targeting the breast cancer immune microenvironment. Nat. Rev. Cancer 24, 554\u2013577 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"2641_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216382","volume":"573","author":"J Natu","year":"2023","unstructured":"Natu, J. & Nagaraju, G. P. Gemcitabine effects on tumor microenvironment of pancreatic ductal adenocarcinoma: Special focus on resistance mechanisms and metronomic therapies. Cancer Lett. 573, 216382 (2023).","journal-title":"Cancer Lett."},{"key":"2641_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.plipres.2021.101112","volume":"83","author":"Y Zhao Zhao","year":"2021","unstructured":"Zhao Zhao, Y., Hasse, S. & Bourgoin, S. G. Phosphatidylserine-specific phospholipase A1: A friend or the devil in disguise. Prog. Lipid Res. 83, 101112 (2021).","journal-title":"Prog. Lipid Res."},{"key":"2641_CR19","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ebiom.2016.02.024","volume":"6","author":"RB Holmgaard","year":"2016","unstructured":"Holmgaard, R. B. et al. Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors. EBioMedicine 6, 50\u201358 (2016).","journal-title":"EBioMedicine"},{"key":"2641_CR20","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1042\/BST20150245","volume":"44","author":"D Achkova","year":"2016","unstructured":"Achkova, D. et al. Role of the colony-stimulating factor (CSF)\/CSF-1 receptor axis in cancer. Biochem Soc. Trans. 44, 333\u2013341 (2016).","journal-title":"Biochem Soc. Trans."},{"key":"2641_CR21","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/neuonc\/nov245","volume":"18","author":"N Butowski","year":"2016","unstructured":"Butowski, N. et al. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol. 18, 557\u2013564 (2016).","journal-title":"Neuro Oncol."},{"key":"2641_CR22","doi-asserted-by":"publisher","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-23-0576","volume":"29","author":"V Fermi","year":"2023","unstructured":"Fermi, V. et al. Effective Reprogramming of Patient-Derived M2-Polarized Glioblastoma-Associated Microglia\/Macrophages by Treatment with GW2580. Clin. Cancer Res 29, 4685\u20134697 (2023).","journal-title":"Clin. Cancer Res"},{"key":"2641_CR23","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.3337","volume":"19","author":"SM Pyonteck","year":"2013","unstructured":"Pyonteck, S. M. et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 19, 1264\u20131272 (2013).","journal-title":"Nat. Med."},{"key":"2641_CR24","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad3018","volume":"352","author":"DF Quail","year":"2016","unstructured":"Quail, D. F. et al. The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science 352, aad3018 (2016).","journal-title":"Science"},{"key":"2641_CR25","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1158\/1535-7163.MCT-20-0591","volume":"20","author":"T Fujiwara","year":"2021","unstructured":"Fujiwara, T. et al. CSF1\/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment. Mol. Cancer Ther. 20, 1388\u20131399 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"2641_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107126","volume":"202","author":"Q Lv","year":"2024","unstructured":"Lv, Q. et al. CSF1R inhibition reprograms tumor-associated macrophages to potentiate anti-PD-1 therapy efficacy against colorectal cancer. Pharm. Res 202, 107126 (2024).","journal-title":"Pharm. Res"},{"key":"2641_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15290-0","volume":"11","author":"M Yin","year":"2020","unstructured":"Yin, M. et al. Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction. Nat. Commun. 11, 1833 (2020).","journal-title":"Nat. Commun."},{"key":"2641_CR28","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","volume":"74","author":"Y Zhu","year":"2024","unstructured":"Zhu, Y. et al. CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res 74, 5057\u20135069 (2024).","journal-title":"Cancer Res"},{"key":"2641_CR29","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.pharmthera.2018.04.008","volume":"189","author":"T Sch\u00f6neberg","year":"2018","unstructured":"Sch\u00f6neberg, T., Meister, J., Knierim, A. B. & Schulz, A. The G protein-coupled receptor GPR34 - The past 20 years of a grownup. Pharmacol. Ther. 189, 71\u201388 (2018).","journal-title":"Pharmacol. Ther."},{"key":"2641_CR30","doi-asserted-by":"publisher","first-page":"e0183572","DOI":"10.1371\/journal.pone.0183572","volume":"12","author":"F Heinrich","year":"2017","unstructured":"Heinrich, F. et al. Morphologic, phenotypic, and transcriptomic characterization of classically and alternatively activated canine blood-derived macrophages in vitro. PLoS One 12, e0183572 (2017).","journal-title":"PLoS One"},{"key":"2641_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45046-z","volume":"15","author":"T Izume","year":"2024","unstructured":"Izume, T. et al. Structural basis for lysophosphatidylserine recognition by GPR34. Nat. Commun. 15, 902 (2024).","journal-title":"Nat. Commun."},{"key":"2641_CR32","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.immuni.2021.05.007","volume":"54","author":"X Wang","year":"2021","unstructured":"Wang, X. et al. GPR34-mediated sensing of lysophosphatidylserine released by apoptotic neutrophils activates type 3 innate lymphoid cells to mediate tissue repair. Immunity 54, 1123\u20131136 (2021).","journal-title":"Immunity"},{"key":"2641_CR33","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1038\/s41590-024-01973-z","volume":"25","author":"J Yan","year":"2024","unstructured":"Yan, J. et al. GPR34 is a metabolic immune checkpoint for ILC1-mediated antitumor immunity. Nat. Immunol. 25, 2057\u20132067 (2024).","journal-title":"Nat. Immunol."},{"key":"2641_CR34","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3389\/fimmu.2014.00402","volume":"5","author":"SS Bohlson","year":"2014","unstructured":"Bohlson, S. S. et al. Complement, c1q, and c1q-related molecules regulate macrophage polarization. Front. Immunol. 5, 402 (2014).","journal-title":"Front. Immunol."},{"key":"2641_CR35","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.trecan.2022.02.006","volume":"8","author":"M Revel","year":"2022","unstructured":"Revel, M., Saut\u00e8s-Fridman, C., Fridman, W. H. & Roumenina, L. T. C1q+ macrophages: passengers or drivers of cancer progression. Trends Cancer 8, 517\u2013526 (2022).","journal-title":"Trends Cancer"},{"key":"2641_CR36","doi-asserted-by":"crossref","unstructured":"Zhang, S. et al. C1q(+) tumor-associated macrophages contribute to immunosuppression through fatty acid metabolic reprogramming in malignant pleural effusion. J. Immunother. Cancer 11, e007441 (2023).","DOI":"10.1136\/jitc-2023-007441"},{"key":"2641_CR37","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.ccell.2021.04.016","volume":"39","author":"L Dong","year":"2021","unstructured":"Dong, L. et al. The loss of RNA N(6)-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8(+) T cell dysfunction and tumor growth. Cancer Cell 39, 945\u2013957 (2021).","journal-title":"Cancer Cell"},{"key":"2641_CR38","doi-asserted-by":"publisher","first-page":"472","DOI":"10.4049\/jimmunol.1601445","volume":"198","author":"MC Pulanco","year":"2017","unstructured":"Pulanco, M. C. et al. Complement Protein C1q Enhances Macrophage Foam Cell Survival and Efferocytosis. J. Immunol. 198, 472\u2013480 (2017).","journal-title":"J. Immunol."},{"key":"2641_CR39","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.cell.2019.05.054","volume":"178","author":"DA Jaitin","year":"2019","unstructured":"Jaitin, D. A. et al. Lipid-Associated Macrophages Control Metabolic Homeostasis in a Trem2-Dependent Manner. Cell 178, 686\u2013698 (2019).","journal-title":"Cell"},{"key":"2641_CR40","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/s44161-023-00354-3","volume":"2","author":"MT Patterson","year":"2023","unstructured":"Patterson, M. T. et al. Trem2 promotes foamy macrophage lipid uptake and survival in atherosclerosis. Nat. Cardiovasc. Res. 2, 1015\u20131031 (2023).","journal-title":"Nat. Cardiovasc. Res."},{"key":"2641_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.155911","volume":"155","author":"W Yu","year":"2024","unstructured":"Yu, W. et al. Myeloid Trem2 ameliorates the progression of metabolic dysfunction-associated steatotic liver disease by regulating macrophage pyroptosis and inflammation resolution. Metabolism 155, 155911 (2024).","journal-title":"Metabolism"},{"key":"2641_CR42","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jhep.2023.02.032","volume":"79","author":"J Tan","year":"2023","unstructured":"Tan, J. et al. TREM2(+) macrophages suppress CD8(+) T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma. J. Hepatol. 79, 126\u2013140 (2023).","journal-title":"J. Hepatol."},{"key":"2641_CR43","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.ccell.2024.05.001","volume":"42","author":"J Zhong","year":"2024","unstructured":"Zhong, J. et al. Distinct roles of TREM2 in central nervous system cancers and peripheral cancers. Cancer Cell 42, 968\u2013984 (2024).","journal-title":"Cancer Cell"},{"key":"2641_CR44","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1038\/s41467-025-57024-0","volume":"16","author":"H Cui","year":"2025","unstructured":"Cui, H. et al. TREM2 promotes lung fibrosis via controlling alveolar macrophage survival and pro-fibrotic activity. Nat. Commun., 16, 1761 (2025).","journal-title":"Nat. Commun.,"},{"key":"2641_CR45","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.immuni.2022.11.013","volume":"56","author":"X Wang","year":"2023","unstructured":"Wang, X. et al. Prolonged hypernutrition impairs TREM2-dependent efferocytosis to license chronic liver inflammation and NASH development. Immunity 56, 58\u201377 (2023).","journal-title":"Immunity"},{"key":"2641_CR46","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1053\/j.gastro.2025.01.244","volume":"168","author":"D Yang","year":"2025","unstructured":"Yang, D. et al. TREM2 Depletion in Pancreatic Cancer Elicits Pathogenic Inflammation and Accelerates Tumor Progression via Enriching IL-1\u03b2(+) Macrophages. Gastroenterology 168, 1153\u20131169 (2025).","journal-title":"Gastroenterology"},{"key":"2641_CR47","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/s13046-024-03255-w","volume":"43","author":"C Liu","year":"2024","unstructured":"Liu, C. et al. SPP1+\u2009macrophages promote head and neck squamous cell carcinoma progression by secreting TNF-\u03b1 and IL-1\u03b2. J. Exp. Clin. Cancer Res 43, 332 (2024).","journal-title":"J. Exp. Clin. Cancer Res"},{"key":"2641_CR48","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.ccell.2023.04.018","volume":"41","author":"X Liu","year":"2023","unstructured":"Liu, X. et al. Context-dependent activation of STING-interferon signaling by CD11b agonists enhances anti-tumor immunity. Cancer Cell 41, 1073\u20131090 (2023).","journal-title":"Cancer Cell"},{"key":"2641_CR49","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41586-023-06685-2","volume":"623","author":"N Caronni","year":"2023","unstructured":"Caronni, N. et al. IL-1\u03b2(+) macrophages fuel pathogenic inflammation in pancreatic cancer. Nature 623, 415\u2013422 (2023).","journal-title":"Nature"},{"key":"2641_CR50","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.immuni.2023.06.017","volume":"56","author":"A Sattiraju","year":"2023","unstructured":"Sattiraju, A. et al. Hypoxic niches attract and sequester tumor-associated macrophages and cytotoxic T cells and reprogram them for immunosuppression. Immunity 56, 1825\u20131843 (2023).","journal-title":"Immunity"},{"key":"2641_CR51","doi-asserted-by":"crossref","unstructured":"Sacristan Santos V. et al. Reprogramming tumor-associated macrophages using STING or TLR agonists: a promising strategy to enhance immunotherapy in hormone-dependent cancers. J. Immunother. Cancer 13, e010950 (2025).","DOI":"10.1136\/jitc-2024-010950"},{"key":"2641_CR52","first-page":"1352","volume":"78","author":"Y LI","year":"2023","unstructured":"LI, Y. et al. Nicotinamide N -methyltransferase promotes M2 macrophage polarization by IL6 and MDSC conversion by GM-CSF in gallbladder carcinoma. Hepatology 78, 1352\u20131367 (2023).","journal-title":"Hepatology"},{"key":"2641_CR53","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41577-019-0240-6","volume":"20","author":"AC Doran","year":"2020","unstructured":"Doran, A. C. et al. Efferocytosis in health and disease. Nat. Rev. Immunol. 20, 254\u2013267 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"2641_CR54","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41573-022-00470-y","volume":"21","author":"P Mehrotra","year":"2022","unstructured":"Mehrotra, P. & Ravichandran, K. S. Drugging the efferocytosis process: concepts and opportunities. Nat. Rev. Drug Discov. 21, 601\u2013620 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2641_CR55","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1189\/jlb.0307192","volume":"82","author":"D Cui","year":"2007","unstructured":"Cui, D. et al. Pivotal advance: macrophages become resistant to cholesterol-induced death after phagocytosis of apoptotic cells. J. Leukoc. Biol. 82, 1040\u20131050 (2007).","journal-title":"J. Leukoc. Biol."},{"key":"2641_CR56","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.cell.2011.04.005","volume":"145","author":"KJ Moore","year":"2011","unstructured":"Moore, K. J. & Tabas, I. Macrophages in the pathogenesis of atherosclerosis. Cell 145, 341\u2013355 (2011).","journal-title":"Cell"},{"key":"2641_CR57","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1126\/science.abl4430","volume":"375","author":"MH Raymond","year":"2022","unstructured":"Raymond, M. H. et al. Live cell tracking of macrophage efferocytosis during Drosophila embryo development in vivo. Science 375, 1182\u20131187 (2022).","journal-title":"Science"},{"key":"2641_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46735-5","volume":"15","author":"M Cheng","year":"2024","unstructured":"Cheng, M. et al. CD276-dependent efferocytosis by tumor-associated macrophages promotes immune evasion in bladder cancer. Nat. Commun. 15, 2818 (2024).","journal-title":"Nat. Commun."},{"key":"2641_CR59","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.immuni.2020.01.014","volume":"52","author":"Y Zhou","year":"2020","unstructured":"Zhou, Y. et al. Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R-Dependent STING Activation by Tumor-Derived cGAMP. Immunity 52, 357\u2013373 (2020).","journal-title":"Immunity"},{"key":"2641_CR60","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/s41586-024-07172-y","volume":"628","author":"T Tufan","year":"2024","unstructured":"Tufan, T. et al. Rapid unleashing of macrophage efferocytic capacity via transcriptional pause release. Nature 628, 408\u2013415 (2024).","journal-title":"Nature"},{"key":"2641_CR61","volume":"11","author":"SM Hong","year":"2024","unstructured":"Hong, S. M. et al. NAMPT-Driven M2 Polarization of Tumor-Associated Macrophages Leads to an Immunosuppressive Microenvironment in Colorectal Cancer. Adv. Sci. (Weinh.) 11, e2303177 (2024).","journal-title":"Adv. Sci. (Weinh.)"},{"key":"2641_CR62","doi-asserted-by":"crossref","unstructured":"Hou, Z. et al. Loss of Annexin A1 in macrophages restrains efferocytosis and remodels immune microenvironment in pancreatic cancer by activating the cGAS\/STING pathway. J. Immunother. Cancer 12, e009318 (2024).","DOI":"10.1136\/jitc-2024-009318"},{"key":"2641_CR63","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1158\/0008-5472.CAN-21-4260","volume":"82","author":"YT Wei","year":"2022","unstructured":"Wei, Y. T. et al. Thymosin \u03b1-1 Reverses M2 Polarization of Tumor-Associated Macrophages during Efferocytosis. Cancer Res. 82, 1991\u20132002 (2022).","journal-title":"Cancer Res."},{"key":"2641_CR64","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.cytogfr.2025.05.006","volume":"84","author":"DG Argyris","year":"2025","unstructured":"Argyris, D. G. et al. An emerging paradigm of CXCL16 involvement in cancer progression. Cytokine Growth Factor Rev. 84, 87\u2013100 (2025).","journal-title":"Cytokine Growth Factor Rev."},{"key":"2641_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2025.101174","volume":"65","author":"Y Liu","year":"2025","unstructured":"Liu, Y. et al. High metastatic tumor-derived CXCL16 mediates liver colonization metastasis by inducing Kupffer cell polarization via the PI3K\/AKT\/FOXO3a pathway. Neoplasia 65, 101174 (2025).","journal-title":"Neoplasia"},{"key":"2641_CR66","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/j.immuni.2024.04.017","volume":"57","author":"N Srivastava","year":"2024","unstructured":"Srivastava, N. et al. CXCL16-dependent scavenging of oxidized lipids by islet macrophages promotes differentiation of pathogenic CD8(+) T cells in diabetic autoimmunity. Immunity 57, 1629\u20131647 (2024).","journal-title":"Immunity"},{"key":"2641_CR67","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.3390\/ijms22073490","volume":"22","author":"J Korbecki","year":"2021","unstructured":"Korbecki, J. et al. The Role of CXCL16 in the Pathogenesis of Cancer and Other Diseases. Int. J. Mol. Sci. 22, 3490 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"2641_CR68","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/j.neuron.2025.04.003","volume":"113","author":"X Ge","year":"2025","unstructured":"Ge, X. et al. Metabolic reprogramming through histone lactylation in microglia and macrophages recruits CD8(+) T lymphocytes and aggravates spinal cord injury. Neuron 113, 2280\u20132296 (2025).","journal-title":"Neuron"},{"key":"2641_CR69","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.7150\/ijbs.96812","volume":"20","author":"W Jiang","year":"2024","unstructured":"Jiang, W. et al. CD8 T cells induce the peritubular capillary rarefaction during AKI to CKD transition. Int. J. Biol. Sci. 20, 2980\u20132993 (2024).","journal-title":"Int. J. Biol. Sci."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02641-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02641-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02641-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:03:18Z","timestamp":1777334598000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02641-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2641"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02641-4","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"16 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All human sample manipulation involved in this study was in accordance with the Declaration of Helsinki and related ethical norms, and was approved by the Ethics Committee of Tianjin Medical University Cancer Hospital (approval number: EK20240448). All participants signed informed consent forms. All animal procedures involved in this study followed the international guidelines for the care and use of laboratory animals and were approved by the Laboratory Animal Ethics Committee of Tianjin Medical University Cancer Institute and Hospital (approval number: 2021045).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"156"}}